FDA “Critical Path” Will Emphasize Clinical Trial Simulation For Drugs
Executive Summary
FDA's "Critical Path" initiative will encourage drug manufacturers to use computer modeling to improve clinical trial design, Acting Deputy Commissioner for Operations Janet Woodcock, MD, said